Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation (y 2)

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

    
    References:
    1 Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial
      fibrillation in adults: national implications for rhythm management
      and stroke prevention: the AnTicoagulation and Risk Factors in Atrial
      Fibrillation (ATRIA) Study. JAMA 2001; 285:2370-5.
    2 Lloyd-Jones et al. Lifetime Risk for Development of Atrial
      Fibrillation: The Framingham Heart Study. Circulation. 2004;
      110:1042-1046.
    3 Fuster V et al. ACC/AHA/ESC 2006 guidelines for the management of
      patients with atrial fibrillation. European Heart Journal (2006) 27,
      1979-2030.
    4 Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D.
      Impact of atrial fibrillation on the risk of death: the Framingham
      Heart Study. Circulation 1998 Sep 8; 98(10):946-52..
    5 Ringborg et all, Europace 2008 10; 400-411

    FOR MORE INFORMATION PLEASE VISIT:
    Dronedarone press office:
    http://www.dronedarone-atrial-fibrillation-pressoffice.com

MEDIA CONTACT: Philippe BARQUET, Tel: +33(0)6-70-48-61-28, Email: philippe.barquet@sanofi-aventis.com